We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Journal article
Lancet Oncol
09/2017
18
1153 - 1154
Anilides, Antineoplastic Agents, Carcinoma, Renal Cell, Cost-Benefit Analysis, Disease-Free Survival, Drug Costs, Humans, Kidney Neoplasms, Practice Guidelines as Topic, Protein Kinase Inhibitors, Pyridines, State Medicine, Treatment Outcome, United Kingdom